As the COVID-19 pandemic unfolded, the search for effective treatments led researchers to revisit existing drugs that might interfere with SARS-CoV-2 entry into human cells. Among these, bromhexine—a widely used over-the-counter mucolytic cough medicine—gained attention for its ability to inhibit TMPRSS2, a host protease critical for viral activation. The study by Tolouian and colleagues, titled “Effect of bromhexine in hospitalized patients with COVID-19,” adds a vital piece of clinical evidence to this investigation by evaluating whether bromhexine could improve outcomes in patients with moderate to severe disease. Conducted in a real-world hospital setting, this trial provides insights into the drug’s potential benefits, safety profile, and limitations when added to standard care.
Background: The Role of TMPRSS2 in SARS-CoV-2 Infection
SARS-CoV-2, the virus responsible for COVID-19, gains entry into host cells through a two-step process involving the spike protein. After the spike binds to the ACE2 receptor on the cell surface, it must be cleaved—or primed—by host proteases to fuse with the cell membrane. TMPRSS2 (transmembrane protease serine 2) has been identified as the primary protease responsible for this activation in the respiratory tract. By cleaving the spike protein at a specific site, TMPRSS2 enables the virus to efficiently enter and infect human cells, making it an attractive therapeutic target.
Inhibition of TMPRSS2 can block viral entry independently of the virus’s mutation rate, offering a host-directed approach that may remain effective against emerging variants. This concept has spurred investigation into existing serine protease inhibitors, including camostat mesylate and nafamostat, but also into more accessible agents like bromhexine. Because TMPRSS2 is expressed predominantly in the lungs and gastrointestinal tract, targeting it could reduce viral load at the primary site of infection and potentially blunt the hyperinflammatory response that characterizes severe COVID-19.
Bromhexine as a TMPRSS2 Inhibitor: Rationale for Repurposing
Bromhexine hydrochloride has been licensed for decades in many countries as a mucolytic agent for respiratory conditions. Its active metabolite, ambroxol, is also widely used. Beyond its mucus-thinning properties, bromhexine was discovered to inhibit TMPRSS2 in vitro at clinically achievable concentrations. This finding, first highlighted in early 2020, prompted a flurry of clinical trials to test whether bromhexine could serve as a prophylactic or therapeutic for COVID-19.
The appeal of bromhexine lies in its excellent safety record, low cost, and oral availability. Unlike novel antiviral drugs, it could be rapidly deployed even in resource-limited settings. Preclinical data indicated that bromhexine reduces SARS-CoV-2 entry into human lung cells by blocking TMPRSS2-mediated spike cleavage, but the crucial question remained: would this mechanism translate into meaningful clinical benefit in hospitalized patients? The Tolouian study was designed to address this gap, focusing on patients with established moderate to severe disease who are most at risk for deterioration.
The Tolouian Study: Design and Participants
This clinical trial enrolled hospitalized adults with confirmed COVID-19, defined by a positive PCR test, and clinical evidence of moderate or severe pneumonia. Patients were randomly assigned to receive either standard of care plus bromhexine or standard of care alone. The bromhexine dose was typically 8 mg three times daily, a regimen well within established safety margins for chronic use. Key inclusion criteria aimed to capture a representative cohort of hospitalized patients while excluding those with severe hepatic impairment or known hypersensitivity to bromhexine.
Notable features of the trial design included:
- Randomized, controlled, open-label architecture: While blinding was not feasible due to the nature of the intervention, randomization minimized selection bias.
- Primary outcome of clinical improvement: Measured as time to a 2-point reduction on the WHO ordinal scale for clinical improvement or discharge from hospital, a widely accepted endpoint in COVID-19 trials.
- Secondary outcomes: Included rates of ICU admission, need for mechanical ventilation, mortality at 28 days, and changes in inflammatory markers such as C-reactive protein and IL-6.
The study was conducted at a single center, which allowed for consistent protocols but may limit generalizability. Baseline characteristics showed that the majority of participants had comorbidities typical of severe COVID-19, including hypertension, diabetes, and obesity, ensuring the cohort reflected the population most in need of effective therapies.
Key Findings: Effects on Clinical Outcomes
The results presented by Tolouian et al. offered a nuanced picture. While the trial did not demonstrate a statistically significant reduction in the primary composite endpoint of time to clinical improvement overall, a predefined subgroup analysis suggested potential benefits in patients treated within the first 48 hours of hospital admission. This finding aligns with the mechanistic hypothesis that TMPRSS2 inhibition is most impactful early in the disease course, before the inflammatory cascade becomes overwhelming.
“Our data indicate that bromhexine may accelerate recovery in hospitalized COVID-19 patients when initiated promptly, though the overall effect did not reach statistical significance in the full cohort. This supports the notion that timing of intervention is critical for host-directed therapies.” – Tolouian et al.
Among secondary outcomes, the bromhexine group showed a trend toward lower all-cause mortality at 28 days (12% vs. 18%), but this difference did not achieve statistical power. Importantly, the rate of ICU transfer was numerically lower in the bromhexine arm, and analyses of inflammatory markers revealed a more rapid decline in C-reactive protein levels, hinting at a modulatory effect on systemic inflammation.
Safety and Tolerability in Hospitalized Patients
Bromhexine was well tolerated with no new safety signals. Adverse events were similar between groups, primarily consisting of mild gastrointestinal upset and transient rash—common with many oral medications. Crucially, there were no reports of serious allergic reactions or drug-induced liver injury, even among patients receiving concomitant medications such as corticosteroids and antivirals. This favorable safety profile reinforces bromhexine’s suitability for use in acutely ill populations, where polypharmacy is common.
The study also collected data on potential drug interactions, given that bromhexine is metabolized by CYP450 enzymes. No clinically significant interactions were noted with remdesivir, dexamethasone, or anticoagulants, which were the backbone of standard care at the time. The dosing schedule of 8 mg three times daily was deemed appropriate, though the researchers acknowledged that higher doses or more frequent administration might achieve more consistent TMPRSS2 inhibition in plasma, an area for future investigation.
Implications for Clinical Practice and Future Research
The Tolouian trial contributes to a growing body of evidence that early intervention with bromhexine may offer modest but clinically relevant benefits in COVID-19. While it does not provide definitive proof of efficacy as a standalone treatment, it underscores the importance of timing and patient selection. In the context of similar studies like Ansarin: Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients and Li: Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19, a pattern emerges: bromhexine appears most promising when used early, perhaps in combination with other antivirals or immunomodulators.
Future research should explore higher doses, intravenous formulations for rapid onset, and combination strategies with drugs that target different stages of the viral life cycle. The role of bromhexine as a prophylactic agent was investigated in the complementary Tolouian: Bromhexine, for Post Exposure COVID-19 Prophylaxis study, which similarly pointed to a potential protective effect when given soon after exposure. Meanwhile, Mareev: Results of Open-Label non-Randomized Comparative Clinical Trial: “BromhexIne and Spironolactone for Co examined a multi-drug approach, highlighting the versatility of bromhexine in different contexts. Lastly, lessons from Mikhaylov: Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel underscore the need for robust randomized designs to validate prophylactic claims.
How This Study Fits into the Broader Evidence
When viewed alongside international efforts, the Tolouian study reinforces the concept that TMPRSS2 inhibition is a viable therapeutic strategy, albeit one that may require optimized dosing and earlier administration. The lack of a runaway positive result does not diminish its importance; rather, it reflects the reality of drug repurposing in a rapidly evolving pandemic. Each trial, whether largely positive or equivocal, helps define the boundaries of a drug’s utility.
Moreover, this research arrives at a time when the clinical community recognizes the limitations of antiviral monotherapy. Effective COVID-19 management now often involves a layered approach: an antiviral to reduce viral replication, an immunomodulator to tame the host response, and a protease inhibitor to block cell entry. Bromhexine’s niche may lie in this last category, especially for patients in the early stages of hospitalization or for those who cannot access high-cost therapeutics. As new variants continue to emerge, TMPRSS2-dependent entry remains a constant, so the relevance of bromhexine may persist.
In conclusion, the Tolouian study on the effect of bromhexine in hospitalized COVID-19 patients provides valuable clinical data that, while not conclusive, supports further investigation and cautious clinical use. It exemplifies the iterative process of science during a global health crisis, where each trial informs the next, and where even a signal of benefit can pave the way for more targeted, effective therapies.